A recent randomized crossover trial uncovered a potential breakthrough for patients with advanced non-small cell lung cancer (NSCLC). The study suggests that opting for a fuller breakfast, as opposed to a low-fat breakfast, may significantly increase the concentration of a key treatment, alectinib, in the blood. This promising finding may potentially translate into improved survival rates for NSCLC patients.
Alectinib is a small-molecule kinase inhibitor. Initially receiving accelerated approval from the U.S. Food and Drug Administration (FDA) in December 2015, the drug obtained regular approval in 2017 for treating anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC. The drug was found to be safe and effective and has become a first-line treatment for this advanced form of lung cancer….